Literature DB >> 23440982

Orbital floor triamcinolone causing Cushing's syndrome in a patient treated with Kaletra for HIV 1.

Hannah Zelie Ruth McConkey1, Helen Williams, Ranjababu Kulasegaram, Elizabeth Graham.   

Abstract

We report the first known case of iatrogenic cushingoid features following orbital floor triamcinolone, a synthetic corticosteroid, in a patient taking Kaletra (200 mg lopinavir/50 mg ritonavir) twice daily and Truvada (tenofovir/emtricitabine) once daily for HIV 1. Previous reports have included similar findings following epidural triamcinolone injections and with inhaled fluticasone.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23440982      PMCID： PMC3597379          DOI： 10.1136/bcr.02.2012.5849

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  1 in total

1.  Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.

Authors:  Roshan Ramanathan; Alice K Pau; Kristin H Busse; Marina Zemskova; Lynnette Nieman; Richard Kwan; Jean H Hammer; JoAnn M Mican; Frank Maldarelli
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079
  1 in total
  3 in total

1.  Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.

Authors:  Emilie R Elliot; Aikaterini Theodoraki; Lakshmi R Jain; Neal J Marshall; Marta Boffito; Stephanie E Baldeweg; Laura J Waters
Journal:  Clin Med (Lond)       Date:  2016-10       Impact factor: 2.659

2.  Iatrogenic Cushing's Syndrome Following Intra-Articular Triamcinolone Injection in an HIV-Infected Patient on Cobicistat Presenting as a Pulmonary Embolism: Case Report and Literature Review.

Authors:  Marjan Alidoost; Gabriella A Conte; Khushboo Agarwal; Michael P Carson; Danielle Lann; Diane Marchesani
Journal:  Int Med Case Rep J       Date:  2020-06-09

Review 3.  What we have to know about corticosteroids use during Sars-Cov-2 infection.

Authors:  F Ferraù; F Ceccato; S Cannavò; C Scaroni
Journal:  J Endocrinol Invest       Date:  2020-08-28       Impact factor: 4.256
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.